Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1652W HIGH $0.83
Volume
2.03 M
Value Traded
897.32 K
Short % Float
2.98%
Days to Cover
1.0
+33.39%Week
-10.33%1 Month
+31.91%3 Month
-13.17%6 Month
-99.81%5 Year
-99.92%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
31.20 M
EPS (TTM)
-0.24
P/E Ratio
-
Ent. Value
42.71 M
Total Shares
100.63 M
Float Shares
76.60 M
Insiders
23.88%
Institutions
7.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
COSM Catalyst Timeline
Dated clinical, regulatory and corporate events for Cosmos Health Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cosmos Health Inc.
2Total events
1Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How COSM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every COSM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Siokas GrigoriosDirector, Officer (Chief Executive Officer), 10% Owner | Buy | 349,825 14,597,917 held | $0.20 | 07/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in COSM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in COSM for Q2 2026. | ||||
Ownership Trends
COSM Short Interest
Shares sold short, counted twice a month.
2.98%
Short % of Float
of tradable shares sold short
2.3M
Shares Sold Short
-10.7% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
2.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How COSM ranks across every disease it competes in
Competitive Position is a premium feature
See how COSM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCOSM News
COSM▲ +11.4%on this news· ran to +24% by day 1
Cosmos Health's U.S. Active Subscriptions Surpass 12,000, Up 92% in Two Weeks
Cosmos Health reported a significant increase in U.S. active subscriptions, surpassing 12,000, which reflects a 92% growth in just two weeks. The monthly subscription value also rose by 94%, reaching nearly $1.8 million. This growth is attributed to the company's direct-to-consumer subscription model launched earlier this year.
Read more →COSM▲ +5.5%on this news· ran to +18% by day 1shared move
Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target
Noble Capital Markets has initiated equity research coverage on Cosmos Health with an Outperform rating and a price target of $1.40 per share. The report highlights the company's shift towards higher-margin revenue, driven by its proprietary products and contract manufacturing operations. CEO Greg Siokas expressed enthusiasm for the coverage, emphasizing growth opportunities.
Read more →COSMCosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway
Cosmos Health Inc. has launched its e-commerce and subscription services in Australia, New Zealand, and the broader Oceania region. Sales have commenced, capitalizing on the growing demand for health and wellness products. The company reported strong growth in its U.S. market, with nearly 9,000 active subscriptions. CEO Greg Siokas emphasized the global ambition of the company.
Read more →COSMCosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion
Cosmos Health CEO Greg Siokas reported a record revenue of approximately $54.3 million for the first nine months of 2026, marking a 19% increase year-over-year. The company anticipates full-year revenue will exceed $90 million, driven by growth in its U.S. subscription business and an expanded contract manufacturing pipeline. Siokas emphasized the importance of improving revenue quality and achieving sustainable profitability.
Read more →COSMCosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days
Cosmos Health anticipates U.S. revenue of approximately $15 million for Q4 2026, with a gross profit of about $10.5 million. Active subscriptions surged by 42% to 8,940 in just five days, contributing significantly to revenue. The company expects strong growth momentum, particularly in December, driven by increased marketing and customer acquisition efforts.
Read more →COSMCosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription
Cosmos Health has reported reaching 6,287 active subscriptions in the U.S. as of October 14, 2026, with most added since mid-September. The company noted that 60.5% of online checkout orders included a subscription, which has risen to over 75% recently. The average subscription includes 2.4 product units, contributing to a monthly subscription value of $919,945. The subscription model, launched in July 2026, is seen as central to enhancing customer relationships and increasing lifetime value.
Read more →COSM▲ +9.5%on this newsshared move
Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days
Cosmos Health Inc. reported record direct-to-consumer sales exceeding $92,000 in a single day on October 11, 2026. Over the past 30 days, total sales reached $902,000, with a significant increase in average daily sales. The company anticipates annual revenue of over $23 million for its U.S. products within the next 12 to 18 months, leveraging direct consumer relationships.
Read more →COSMCosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
Cosmos Health Inc. reported a record preliminary revenue of approximately $54.3 million for the nine months ending September 30, 2026, marking a 19% increase year-over-year. The third quarter also saw record revenue of $17.4 million, surpassing previous highs. The company reaffirmed its outlook for 2026, expecting revenue to exceed $90 million, driven by growth across its core segments.
Read more →COSMCosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
Cosmos Health Inc. has expanded its brand portfolio to over 15 proprietary brands sold in more than 40 countries, addressing a global market valued at approximately $946 billion. The company emphasizes quality control through in-house manufacturing and has established strong distribution channels across various regions. Its flagship brand, Sky Premium Life, has seen significant growth, particularly in the Gulf and European markets. The company anticipates continued growth driven by its diverse product offerings and strategic partnerships.
Read more →COSM▲ +13.7%on this newsshared move
Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue
Cosmos Health's subsidiary, CosmoFarm, reported record annualized revenue surpassing $60 million, reflecting a 4.3x increase since acquisition. The company has expanded its customer base significantly, now serving around 360 daily pharmacies. Investments in robotics and AI are expected to further enhance capacity, with projections indicating potential revenue exceeding $100 million in the future.
Read more →COSM▲ +5.3%on this news· ran to +20% by day 1shared move
Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline
Cosmos Health's subsidiary, Cana Laboratories, has achieved over $20 million in implied revenue from its contract manufacturing pipeline, with gross profits exceeding $18 million. The pipeline has expanded significantly, tripling since the beginning of 2026, and is expected to continue growing as new agreements are signed. The company aims for over $10 million in recurring annual gross profit at full capacity.
Read more →COSMCosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
Cosmos Health Inc. has announced new five-year manufacturing agreements with Target Pharma, totaling approximately 5.2 million units. This development has led to a 31% increase in Cana Laboratories' orderbook since June 2026, now exceeding 32.7 million units. The agreements enhance the company's portfolio in dermatology and anti-infectives, reflecting significant growth and diversification.
Read more →COSM▲ +12.7%on this news· ran to +24% by day 3shared move
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
Cosmos Health Inc. has engaged Prime Ledger Inc. to structure a tokenized financing model for its CCX0722 intellectual property, an ingestible hydrogel-based medical device aimed at weight management. This innovative approach allows the company to raise capital without diluting its stock. The global weight management market is projected to grow significantly, providing a favorable backdrop for CCX0722's development.
Read more →COSMCosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
Cosmos Health Inc. announced a new five-year contract manufacturing agreement with Viofar for 2.5 million units of ROSARTIA, enhancing its orderbook to over 27.5 million units. The agreement will bolster Cana Laboratories' production capabilities in cardiovascular pharmaceuticals and provide greater visibility into future cash flows. This expansion reflects Cosmos Health's strategy to strengthen its manufacturing operations and relationships with pharmaceutical companies.
Read more →COSM▼ -5.7%on this newsshared move
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market
Cosmos Health has launched its veterinary antimicrobial product, C-ScrubVet, in the UK, targeting the growing $69 billion global animal health market. The product is formulated for various animals and is certified for veterinary use. Initial sales will focus on e-commerce, with plans for expansion into retail and veterinary clinics in Europe starting in Q4 2026. This launch is expected to support the company’s revenue growth targets for 2029.
Read more →COSM▲ +18.7%on this news
Cosmos Health: A Company Transformed — 2026 Year-to-Date
Cosmos Health Inc. has reported significant financial growth from January to August 2026, achieving record revenues in every quarter. The company has strengthened its balance sheet by reducing liabilities and increasing stockholders' equity. Key developments include successful product placements in major UK retailers and a strategic international expansion, alongside a growing proprietary IP portfolio.
Read more →COSMCosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions
Cosmos Health has successfully retired an $8 million convertible note a year ahead of schedule, enhancing its balance sheet and eliminating future dilution. The company has also streamlined its capital structure and reduced operating cash requirements by over 30%. With record revenue growth and a strong liquidity position, Cosmos is poised for its next growth phase, including a $5 million share repurchase program.
Read more →COSMCosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
Cosmos Health Inc. forecasts that its product Oliv18™ will generate over $6 million in annual revenue and approximately $4.3 million in gross profit within the next 12 to 18 months. This growth is attributed to a strategic rollout starting with e-commerce, targeting the cardiovascular health and antioxidant markets. The company emphasizes the scientific backing of its products as a key driver for consumer demand.
Read more →COSM▲ +11.9%on this newsshared move
Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term
Cosmos Health has entered Saudi Arabia through an exclusive distribution agreement with Innova Healthcare, securing an initial purchase order of 126,000 units of its Sky Premium Life products. The agreement spans five years with potential for renewal and includes rights to distribute new products. This partnership positions Cosmos Health to tap into a rapidly growing nutraceuticals market in Saudi Arabia, projected to reach $5.96 billion by 2033.
Read more →COSM▲ +5.7%on this news
Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels
Cosmos Health Inc. is developing a technology-driven subscription platform for its health products, targeting both consumers and corporate clients. The platform will offer personalized health solutions through various purchasing models, including B2C and B2B subscriptions. Future enhancements may include AI-driven personalization and at-home testing integration. The initiative builds on the successful launch of NOOR Collagen, which has shown promising repeat purchase rates.
Read more →About Cosmos Health Inc.
Headquarters5 AGIOU GEORGIOU, PILEA, THESSALONIKI, J3, 55438
BIOPHARMAWATCH ELITE PLUS
Trade the next COSM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime